MP-453089-1 DIGOXIN AND RISK OF VENTRICULAR TACHYARRHYTHMIA AND DEATH IN ICD RECIPIENTS

Digoxin continues to be used in patients with heart failure reduced ejection fraction (HFrEF), especially among those atrial fibrillation (AF) difficult control ventricular response. However, some studies have shown digoxin use associated adverse outcomes including increased mortality. There are limited data on whether is risk of tachycardia/ventricular (VT/VF) implantable cardioverter defibrillator (ICD) recipients. We sought assess would VT/VF HFrEF who were implanted a primary prevention ICD landmark clinical trials. Our study cohort consisted an or cardiac resynchronization therapy-defibrillator (CRT-D) enrolled the four MADIT Propensity score for at baseline was developed using wide variety measures logistic regression model stepwise variable selection approach. All potential variables which met significance level <0.10 included propensity model. Additionally, multivariate proportional hazards endpoint VT/VF. This along quintile stratification endpoints VT/VF, death and VT/VF/death. At baseline, 1155 4499 (26%). Table 1. From statistical models both adjustment stratification, prescribed exhibited statistically significant 28% [HR 1.28 (1.10-1.50); p=0.002; Figure 1A], 38% composite 1.38 (1.21-1.58); p<0.0001; 1B]; 64% 1.64; (1.32-2.04); p<0.0001]. findings suggest that tachyarrhythmic events adds growing evidence certain groups need reconsideration ICD.